Pfizer in talks with India over expedited approval for COVID-19 vaccine
NEW DELHI, May 3 (Reuters) - Pfizer is in discussions with the Indian government seeking an "expedited approval pathway" for its COVID-19 vaccine, its CEO Albert Bourla said on LinkedIn on Monday, announcing a donation of medicines worth more than $70 million.
"Unfortunately, our vaccine is not registered in India although our application was submitted months ago," he said.
"We are currently discussing with the Indian government an expedited approval pathway to make our Pfizer-BioNTech vaccine available for use in the country."
(Reporting by Krishna N. Das; Editing by Tom Hogue)
((Krishna.Das@tr.com; +91 987111 8314;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.